Infinium Pharmachem Limited
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates
What Infinium files
- Others37
- Important9
- Board Meeting8
- Insider Trade5
- Results2
- Dividend/Bonus2
Infinium Pharmachem's board approved annual audited standalone & consolidated results. Standalone net profit was 10.02 Cr; consolidated net profit 14.20 Cr. Key updates: company confirmed proper IPO fund use and operations resumed after a temporary shutdown.
Infinium Pharmachem's manufacturing facility faces temporary GPCB closure for alleged unauthorized water waste disposal. The company is seeking swift revocation. Sales from existing stock will offset turnover impact for April. A Rs. 2 lakh Bank Guarantee is required; further financial impact is currently unquantifiable.
INFINIUM will set up a 1.1 MW DC ground-mounted solar power project at an approximate cost of 4 Cr. This captive investment aims to reduce energy costs for its existing plants and support green initiatives.
Infinium Pharmachem reported a fire in its open stockyard, causing an estimated loss of 0.05 Cr. The incident did not affect main manufacturing operations, and the damage is fully insured. No impact on production.
Infinium Pharmachem has announced a board meeting to consider the financial results for the quarter and half-year. The company has entered a 5-year exclusive distribution agreement with Japan's K Sakai & Company, a well-established chemical distributor with a strong presence in semiconductors, electronics, pharmaceuticals, and agrochemicals. This partnership aims to...